Our Pricing

Mysimba vs Ozempic: Expert UK Pharmacist Comparison

Published on: June 03, 2026

Choosing whether to buy Mysimba vs Ozempic online UK requires understanding how these medications work differently in your body. As a UK-registered pharmacy with thousands of weight management consultations completed, we've prepared this evidence-based comparison to help you and your prescriber identify the most suitable option for your individual circumstances.

How Mysimba and Ozempic Work Differently

Mysimba and Ozempic represent fundamentally different approaches to weight management, each targeting distinct biological pathways. Mysimba contains a fixed-dose combination of naltrexone 8mg and bupropion 90mg per tablet, working centrally in the brain to reduce appetite and food cravings through opioid and dopamine pathway modulation [1]. This oral medication requires no injections and is taken twice daily after a gradual dose escalation period.

Ozempic, by contrast, contains semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. Semaglutide mimics natural GLP-1 hormone activity, slowing gastric emptying, enhancing satiety signals, and improving glycaemic control [2]. Originally licensed for type 2 diabetes management, Ozempic is increasingly prescribed off-label for weight management in the UK, though Wegovy (identical semaglutide formulation) holds specific weight loss licensing from the MHRA.

The mechanism distinction matters clinically: Mysimba modulates central nervous system appetite regulation without affecting blood glucose directly, whilst Ozempic influences both metabolic and appetite pathways through peripheral and central GLP-1 receptor activation [1][2]. Your UK prescriber will assess which mechanism aligns better with your medical history, particularly if you have diabetes, cardiovascular considerations, or contraindications to either drug class.

Clinical Efficacy: What the Trial Data Shows

In the COR-I trial involving 1,742 participants without diabetes, Mysimba produced an average 5.0% total body weight reduction over 56 weeks compared to 1.3% with placebo—a statistically significant difference [1]. Approximately 50% of Mysimba-treated patients achieved at least 5% weight loss, whilst 25% reached 10% or greater reduction. These outcomes represent meaningful clinical benefit, particularly for patients unable or unwilling to use injectable therapies.

The STEP 1 trial evaluated semaglutide 2.4mg (Wegovy dose, identical to higher off-label Ozempic dosing) in 1,961 adults with obesity or overweight plus comorbidities. Participants achieved an average 14.9% body weight reduction over 68 weeks versus 2.4% with placebo [2]. Nearly 70% of semaglutide-treated patients lost at least 10% body weight, with one-third exceeding 20% reduction—substantially higher magnitude than Mysimba trials demonstrated.

Whilst direct head-to-head trials between Mysimba and Ozempic don't exist, the separate placebo-controlled studies suggest semaglutide-based treatments typically produce greater absolute weight loss on average. However, individual response varies considerably, and factors beyond raw efficacy numbers—including administration route preference, side effect tolerance, cost, and contraindications—significantly influence real-world treatment success [1][2].

Realistic Expectations for Weight Loss Outcomes

Clinical trial populations differ from real-world patients, and average outcomes don't predict individual results. Your UK prescriber will discuss realistic expectations based on your starting BMI, metabolic health, lifestyle modifications, and treatment adherence. Both medications require concurrent dietary changes and increased physical activity to optimise results—they are adjuncts to, not replacements for, behaviour modification programmes [3].

Administration, Dosing, and Treatment Schedules

Mysimba follows a four-week dose escalation schedule to minimise gastrointestinal and neuropsychiatric side effects. Week one involves one tablet each morning, increasing to one tablet twice daily in week two, then two tablets morning plus one evening in week three, reaching the maintenance dose of two tablets twice daily (total daily dose: naltrexone 32mg, bupropion 360mg) by week four [1]. Tablets should be swallowed whole without crushing and taken with food to reduce nausea.

Ozempic uses a pre-filled injection pen delivering subcutaneous doses once weekly, typically into the abdomen, thigh, or upper arm. The standard initiation schedule begins with 0.25mg weekly for four weeks (not a therapeutic dose—purely for tolerability), increasing to 0.5mg weekly, with optional escalation to 1mg weekly if additional glycaemic or weight control is needed [2]. When used off-label for weight management, some UK prescribers may recommend the 2mg dose, though this exceeds standard diabetes licensing.

Administration preference varies individually: some patients prefer the convenience and discretion of oral Mysimba tablets, whilst others find once-weekly injections easier to remember than twice-daily dosing. Needle anxiety affects treatment choice for some individuals, though Ozempic pens use very fine 32-gauge needles with minimal discomfort reported in clinical experience.

What Happens If You Miss a Dose

With Mysimba, if you miss a dose and remember within a few hours, take it as soon as possible. If it's nearly time for your next scheduled dose, skip the missed dose entirely—never double up to compensate. For Ozempic, inject the missed dose as soon as you remember if fewer than five days have passed since the scheduled injection; if more than five days have elapsed, skip that dose and resume your normal weekly schedule [1][2].

Common Side Effects and Safety Considerations

Mysimba's most frequently reported side effects include nausea (reported by approximately 30% of trial participants), constipation, headache, vomiting, dizziness, insomnia, and dry mouth [1]. Nausea typically peaks during dose escalation and often improves with continued use. Serious but rare risks include seizures (contraindicated in patients with seizure disorders or eating disorders), hepatotoxicity requiring liver function monitoring, and neuropsychiatric effects including mood changes, anxiety, or suicidal ideation—particularly in patients with pre-existing mental health conditions.

Ozempic commonly causes gastrointestinal symptoms: nausea affects 15-20% of patients, alongside vomiting, diarrhoea, constipation, and abdominal discomfort [2]. These effects generally diminish over several weeks as tolerance develops. More serious concerns include pancreatitis risk (discontinue immediately if severe abdominal pain occurs), gallbladder disease, hypoglycaemia when combined with insulin or sulfonylureas, and theoretical thyroid C-cell tumour risk based on rodent studies—though human relevance remains uncertain.

Both medications carry specific contraindications requiring careful prescriber assessment. Mysimba is contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, opioid dependence, and concurrent MAOI use [1]. Ozempic is contraindicated in personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. Your UK clinical assessment will screen for these conditions before any prescription is issued.

Cost Comparison and UK Availability

Weight management medications represent a significant ongoing investment, and cost considerations influence treatment sustainability for many UK patients. Pricing varies across UK pharmacies and depends on prescribed dose strength and quantity. At Cured Pharmacy, we maintain transparent upfront pricing displayed before your clinical consultation begins, ensuring you understand costs before committing to assessment.

Neither Mysimba nor Ozempic is routinely available through NHS prescription for weight management alone in most UK areas, though exceptional commissioning decisions occur in specific clinical circumstances or geographical regions. Private prescription remains the primary access route for most patients seeking these treatments for weight loss. When comparing costs, consider total monthly expenditure including consultation fees, medication price, and any required monitoring or follow-up appointments.

Generic alternatives don't currently exist for either medication in the UK market, as both remain under patent protection. Some patients explore switching between treatments if initial choice proves unaffordable long-term or if side effects become intolerable. Your prescriber can discuss treatment sequencing strategies if cost or tolerability issues arise during your weight management journey.

Alternative Weight Loss Options at Cured Pharmacy

Beyond Mysimba and Ozempic, Cured Pharmacy offers Wegovy (semaglutide specifically licensed for weight management), providing an MHRA-approved alternative with the same active ingredient as Ozempic but at weight-loss-optimised dosing. All prescription weight loss treatments available through our pharmacy require completion of a free online clinical assessment by a UK-registered prescriber, ensuring safe, appropriate prescribing tailored to your individual medical profile.

Making Your Decision: Which Treatment Suits You?

Selecting between Mysimba and Ozempic involves weighing multiple factors beyond efficacy data alone. Consider your comfort level with daily oral medication versus weekly injections, your previous experience with either drug class, any contraindications in your medical history, your budget for ongoing treatment, and your specific weight loss goals and timeline.

Patients with type 2 diabetes may find Ozempic particularly suitable given its dual glycaemic and weight benefits, whilst those with needle phobia, gastrointestinal sensitivity to GLP-1 agonists, or contraindications to semaglutide might prefer Mysimba's oral administration and different mechanism. Previous unsuccessful trials of one medication don't preclude success with the other, as individual responses vary significantly based on genetic factors, adherence patterns, and concurrent lifestyle modifications [3].

The most effective approach involves collaborative decision-making with your UK prescriber during your clinical consultation. At Cured Pharmacy, our assessment process takes under three minutes to complete online, after which a UK-registered prescriber reviews your medical history, current medications, and weight management goals to recommend the most appropriate treatment. If prescribed, your medication is dispensed from our UK-registered pharmacy and delivered in 100% discreet packaging, typically arriving within 24-48 hours of prescription approval.

Scientific References

1. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Wadden, T. A., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary individually and depend on adherence to treatment, dietary modifications, and physical activity levels. Neither Mysimba nor Ozempic cures obesity—they are adjunct therapies to comprehensive lifestyle interventions.